PMID: 1137386Mar 1, 1975Paper

Gentamicin and gentamicin C1 in the treatment of complicated urinary tract infections: comparative study of efficacy, tolerance, and pharmacokinetics

Antimicrobial Agents and Chemotherapy
A MosegaardP O Madsen

Abstract

The clinical efficacy, patient tolerance, and pharmacokinetics of gentamicin and the single component gentamicin C(1) were studied after single and multiple doses in elderly male patients. Patient tolerance was extremely good at the dose levels used. There was some evidence of renal function impairment due to repeated intramuscular doses of gentamicin, but not gentamicin C(1). The antibiotics were equally effective against the organisms present in the urine of these patients. The pharmacokinetics of the two antibiotic forms were similar, although gentamicin C(1) appeared to have a larger distribution space.

References

Aug 1, 1972·The Journal of Clinical Pharmacology and New Drugs·B R Meyers, S Z Hirschman
Dec 1, 1971·The Journal of Infectious Diseases·J N WilfertC B Smith
Apr 1, 1967·Journal of Pharmaceutical Sciences·J G Wagner, J I Northam
Mar 14, 1964·JAMA : the Journal of the American Medical Association·R D WAGONERJ C HUNT

Citations

Jun 1, 1977·Infection·F H Kayser
Jul 3, 1980·The New England Journal of Medicine·G NicotG Lachatre
Sep 1, 1977·Antimicrobial Agents and Chemotherapy·P G WellingP O Madsen
Apr 1, 1978·Antimicrobial Agents and Chemotherapy·J J SchentagW J Jusko
May 19, 2000·Antimicrobial Agents and Chemotherapy·N IsoherranenS Soback
Feb 26, 1977·Lancet·J J Schentag, W J Jusko
Feb 1, 1976·Journal of Clinical Pharmacology·P G WellingP O Madsen
Nov 1, 1981·Drug Intelligence & Clinical Pharmacy·W S Burkle
Oct 3, 2002·Equine Veterinary Journal·A SteinmanS Soback
Dec 9, 2020·Proceedings of the National Academy of Sciences of the United States of America·Mary E O'SullivanAnthony J Ricci

Related Concepts

Gentacycol
Urinary Tract Infection

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.